Gyre Therapeutics, Inc.

NASDAQ:GYRE

Biotechnology

Healthcare
$4.34 -0.15%

+$0.00 today

Market cap
$475.02M
Beta
4.92
P/E (TTM)
-88.3
EPS (TTM)
-$0.07
52W Low $5.44High $9.42

Volume 0.47M

Average 0.09M

Returns on capital

Gyre Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

4.7%

avg 0.1%

ROIC

5.3%

avg -51.0%

ROA

3.0%

avg -43.7%

Analysis

ROIC is currently the strongest return metric at 5.3% versus its period average of -51.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Weiguo Ye

Chief Operating OfficerUSD 563.41K48700.00K0.72%

Ruoyu Chen

Chief Information OfficerUSD 285.58K5550.00K0.05%

Ying Luo

CEO, President & DirectorUSD 85K61120.00K0.12%

Thomas W. Eastling

Chief Financial OfficerUSD 50K67——

Yue Xiong

Chief Scientific Officer & Director——2.38M2.45%

Jing Liu

Senior Vice President of Platform Chemistry————

Mark Marino

Senior Vice President of Clinical Development————

Jialiang Wang

Executive VP & GM————

Joshua Bergmann

General Counsel & Corporate Secretary————

Seth Goldblum

Senior Vice President of Corporate Development————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 18, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

17

$895,064.76

Net Transaction Value

−$895,064.76

Net selling

Most Active

Ye Weiguo

15 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jun 18, 26

Ye Weiguo

Direct

Sell$19.1K
Jun 11, 26

Ye Weiguo

Direct

Sell$17.3K
Jun 10, 26

Ye Weiguo

Direct

Sell$31.2K
Jun 10, 26

Ye Weiguo

Direct

Sell$39.9K
Jun 9, 26

Ye Weiguo

Direct

Sell$89K
Jun 9, 26

Ye Weiguo

Direct

Sell$18.5K
Jun 5, 26

Ye Weiguo

Direct

Sell$98.6K
Jun 4, 26

Ye Weiguo

Direct

Sell$120K
May 26, 26

Ye Weiguo

Direct

Sell$24.4K
May 22, 26

Ye Weiguo

Direct

Sell$21.3K

1–10 of 17

Summary

Insiders reported 0 buys worth $0.00 and 17 sells worth $895,064.76 over the last 12 months. That adds up to net selling of $895,064.76. Ye Weiguo was the most active insider with 15 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/A-9.1%
+76.0% (5yr)1 analysts
RevenueN/AN/A+4.5%
+22.6% (5yr)1 analysts
Net IncomeN/AN/A+29.7%
+50.8% (5yr)1 analysts
EBITN/AN/A+7.7%
+40.5% (5yr)1 analysts

Analysis

Recent growth has been strongest in Net Income at +29.7% over three years. Forward estimates point to EPS at +76.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Gyre Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about GYRE's management, answered from reported figures.

Who manages GYRE?

Gyre Therapeutics, Inc. (GYRE) lists 10 active executives. The top listed executive is Yue Xiong, Chief Scientific Officer & Director.

Are GYRE insiders buying or selling?

Recent insider activity shows net buying of $12.31M.